Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Epistemonikos ID: 363e377f4d99c3553463c073fdcb1e2eec0fe03e
First added on: Mar 28, 2026